Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells $50,933.96 in Stock

Key Points

• Yajing Chen, CFO of Zai Lab, sold 1,438 shares of stock for approximately $50,934, reducing their ownership by 7.92% to 16,720 shares valued at $592,222.40.
• Zai Lab reported Q2 earnings of ($0.37) per share on revenue of $109.98 million, missing expectations of $125.66 million.
• Institutional investors hold 41.65% of Zai Lab stock, with significant recent activity including purchases by RTW Investments and Mirae Asset Global Investments.

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CFO Yajing Chen sold 1,438 shares of Zai Lab stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $35.42, for a total transaction of $50,933.96. Following the transaction, the chief financial officer directly owned 16,720 shares in the company, valued at $592,222.40. This trade represents a 7.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Yajing Chen also recently made the following trade(s):

• On Friday, August 8th, Yajing Chen sold 4,096 shares of Zai Lab stock. The stock was sold at an average price of $34.01, for a total transaction of $139,304.96.
• On Thursday, June 26th, Yajing Chen sold 2,675 shares of Zai Lab stock. The stock was sold at an average price of $36.13, for a total transaction of $96,647.75.
• On Monday, June 2nd, Yajing Chen sold 9,618 shares of Zai Lab stock. The stock was sold at an average price of $30.00, for a total transaction of $288,540.00.

Zai Lab Price Performance

Shares of NASDAQ ZLAB traded down $0.04 during midday trading on Monday, reaching $35.69. 562,813 shares of the stock traded hands, compared to its average volume of 980,763. The stock has a market capitalization of $3.96 billion, a PE ratio of -17.50 and a beta of 1.03. Zai Lab Limited Unsponsored ADR has a one year low of $16.56 and a one year high of $44.34. The company's 50 day moving average is $36.68 and its 200 day moving average is $33.59.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.37). The company had revenue of $109.98 million for the quarter, compared to the consensus estimate of $125.66 million. Zai Lab had a negative return on equity of 27.32% and a negative net margin of 49.68%. As a group, equities analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current year.

Institutional Investors Weigh In On Zai Lab

Several institutional investors have recently added to or reduced their stakes in ZLAB. RTW Investments LP acquired a new stake in Zai Lab in the fourth quarter worth about $65,714,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Zai Lab by 46,222.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company's stock worth $77,058,000 after acquiring an additional 2,127,598 shares in the last quarter. RA Capital Management L.P. purchased a new position in shares of Zai Lab in the fourth quarter worth about $33,917,000. Principal Financial Group Inc. raised its stake in shares of Zai Lab by 63.6% in the first quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company's stock worth $104,257,000 after purchasing an additional 1,121,856 shares during the last quarter. Finally, MPM Bioimpact LLC purchased a new position in shares of Zai Lab in the fourth quarter worth about $20,952,000. Institutional investors and hedge funds own 41.65% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ZLAB shares. Wall Street Zen downgraded shares of Zai Lab from a "buy" rating to a "hold" rating in a research note on Friday, June 27th. Citigroup reaffirmed a "buy" rating and issued a $69.00 target price (up from $66.00) on shares of Zai Lab in a research note on Monday, August 11th. Finally, Leerink Partners set a $75.00 target price on shares of Zai Lab and gave the stock an "outperform" rating in a research note on Monday, June 30th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Zai Lab has an average rating of "Moderate Buy" and an average price target of $57.22.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.